Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1751 participants.

Also called NCT02648347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,751 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02648347
  • EudraCT 2015-004265-81
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, France, Hungary, Israel, Italy, Malaysia, Mexico, New Zealand, Poland, Puerto Rico, Russia, South Africa, South Korea, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02648347. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2020-06-04 (actual). Results posted on 2022-06-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
Condition
Anemia
Condition
Non-Dialysis-Dependent Chronic Kidney Disease
Intervention (Drug)
Vadadustat
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02648347
Content hash
82998a789f3521ff12ca0c1602d707e5e1743ba7fa873d3ce7ff0d09154ecd20